Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash & Equivalents (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Cash & Equivalents readings, the most recent being $500.8 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 210.2% to $500.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $500.8 million through Dec 2025, up 210.2% year-over-year, with the annual reading at $500.8 million for FY2025, 210.2% up from the prior year.
  • Cash & Equivalents hit $500.8 million in Q4 2025 for Terns Pharmaceuticals, up from $126.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $500.8 million in Q4 2025 and bottomed at $16.8 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $107.2 million, with a median of $80.4 million recorded in 2023.
  • The largest annual shift saw Cash & Equivalents surged 744.98% in 2021 before it crashed 75.14% in 2022.
  • Terns Pharmaceuticals' Cash & Equivalents stood at $47.7 million in 2021, then tumbled by 51.72% to $23.0 million in 2022, then skyrocketed by 247.07% to $79.9 million in 2023, then surged by 101.99% to $161.4 million in 2024, then soared by 210.2% to $500.8 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Cash & Equivalents are $500.8 million (Q4 2025), $126.6 million (Q3 2025), and $146.0 million (Q2 2025).